The combination of nivolumab plus low-dose ipilimumab led to a longer duration of overall survival (OS) versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), independent of PD-L1 expression level, according to a secondary analysis of the CheckMate 227 trial. In the phase III trial presented at the European Society of Medical Oncology ...
New treatment option for first-line treatment of metastatic NSCLC
By Nicola Garrett
1 Oct 2019